Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Feb
25
2011
EPA Issues Final Boiler MACT Rules Michael Best & Friedrich LLP
Mar
10
2013
Wisconsin Department of Natural Resources (WDNR) Draft Guidance on Pollutant (TMDL/WPDES) Permit; Implementation Is Open for Public Comment Michael Best & Friedrich LLP
Aug
8
2013
Wisconsin Governor Walker Signs Wisconsin State Budget Bill Into Law Michael Best & Friedrich LLP
Nov
3
2013
Request for Public Comments by ANVISA (National Sanitary Vigilance Agency) on the Interchangeability of Branded Generic Drugs with Reference Drugs in Brazil Michael Best & Friedrich LLP
Jun
4
2014
Availability of Biosimilar Pathways and Data/Marketing Exclusivity Globally Michael Best & Friedrich LLP
Sep
22
2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 1 of a 5-Part Series Michael Best & Friedrich LLP
Jan
3
2015
FDA’s Second Swing at Proposed FSMA regulations Michael Best & Friedrich LLP
Jan
21
2015
Teva Pharmaceuticals v. Sandoz: Supreme Court Changes Standard of Review in Claim Construction Case Michael Best & Friedrich LLP
Jun
30
2015
AstraZeneca’s Crestor® Patent is Invalidated by the Brazilian Federal Courts Michael Best & Friedrich LLP
Jul
16
2013
Ethanol and Other Biomass Plants No Longer Exempt from Carbon Dioxide Emission Limits: D.C. Circuit Vacates EPA's Three-Year Deferral for Biogenic CO2 Sources Michael Best & Friedrich LLP
Aug
2
2013
Healthcare and Data Exclusivity in Russia – One Year Later Michael Best & Friedrich LLP
Jul
1
2014
Nanotechnology in Food Production: FDA Finalizes Guidance on Manufacturing Process Changes for Food Additives Michael Best & Friedrich LLP
Jun
7
2015
Brazil’s New Biodiversity Law Michael Best & Friedrich LLP
May
5
2016
FDA Issues Deeming Rule regarding Tobacco Products Michael Best & Friedrich LLP
Jul
6
2016
Federal Circuit Rules Biosimilar Notice of Commercial Marketing Mandatory Michael Best & Friedrich LLP
Aug
19
2016
FDA Issues Final Rule on Substances Generally Recognized as Safe Michael Best & Friedrich LLP
Nov
11
2010
Revised Biomass Crop Assistance Program Begins Michael Best & Friedrich LLP
Aug
10
2011
Commercial Biopharma in Wisconsin: What Next? Michael Best & Friedrich LLP
May
19
2012
JOBS Act Update for Biofuels Companies Michael Best & Friedrich LLP
Apr
23
2013
Know Your Rights When the Environmental Protection Agency (EPA) Comes Knocking Michael Best & Friedrich LLP
Jul
9
2013
Seventh Circuit Determines That Failing to Obtain a Prevention of Significant Deterioration (PSD) Permit is a One-Time Violation of the Clean Air Act Michael Best & Friedrich LLP
Aug
9
2013
Recent Decisions involving Section 3(d) of the Indian Patents Act Michael Best & Friedrich LLP
Feb
25
2014
Angels and Early Exits: Sometimes, a Bird in the Bush is Worth More than a Bird in the Hand Michael Best & Friedrich LLP
Jun
13
2014
Supreme Court Rules that Competitors Can Challenge Advertising that is False or Misleading Even if it Complies with Federal Food and Beverage Labeling Laws Michael Best & Friedrich LLP
Jul
30
2014
The Race is on! Anxiously Waiting for the First U.S. Biosimilar to Cross the Finish Line Michael Best & Friedrich LLP
Nov
20
2014
A Report from the “Biosimilars and Biotech: MENA Conference” in Istanbul, Turkey: Part 1 Michael Best & Friedrich LLP
Nov
28
2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 3 of a 5-Part Series Michael Best & Friedrich LLP
Jun
7
2015
Federal Circuit Hears Oral Arguments in Litigation involving the First U.S. Biosimilar Product Michael Best & Friedrich LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins